Should Enveric Biosciences be in Your Stock Portfolio?

This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEC180BO_M.jpg

However, investigations are ongoing against ENVB regarding the proposed acquisition, which could negatively impact the company’s business. The stock has lost 38.3% year-to-date and 60.4% over the past nine months to close Friday’s trading session at $2.63. Moreover, the company is yet to generate revenue, and its losses widened in the second quarter. So, its near-term prospects look uncertain.

Here’s what I think could influence ENVB’s performance in the near term:

Continue reading on StockNews

Add Comment